Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 15, 2021

SELL
$21.26 - $38.85 $15.2 Million - $27.8 Million
-714,500 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$9.82 - $18.27 $7.02 Million - $13.1 Million
714,500 New
714,500 $11.8 Million

Others Institutions Holding CERE

About Cerevel Therapeutics Holdings, Inc.


  • Ticker CERE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 155,752,000
  • Description
  • Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...
More about CERE
Track This Portfolio

Track Boxer Capital, LLC Portfolio

Follow Boxer Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Boxer Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Boxer Capital, LLC with notifications on news.